UCLB

Carbon Re is a climate technology company focused on utilizing artificial intelligence to decarbonize energy-intensive industries such as cement, steel, and glass, which collectively contribute over 20% of global carbon emissions. The company’s Delta Zero platform employs deep learning to facilitate the rapid development and implementation of low-carbon industrial processes, designs, and materials. By integrating continuous improvement methods with AI, Carbon Re aims to enhance operational efficiencies while significantly reducing greenhouse gas emissions in manufacturing. This approach not only targets substantial reductions in carbon emissions but also aims to lower electricity and fuel costs for plants, thereby promoting efficient decarbonization in foundational industries.

Astroscreen Ltd is a London-based company that specializes in developing a software as a service (SaaS) platform aimed at detecting astroturfing campaigns and social media manipulation. Incorporated in 2018, Astroscreen utilizes advanced machine learning techniques alongside human intelligence to identify fake accounts, botnets, and spam on social networks. Its platform supports disinformation analysts by verifying social media influence engagement and cleaning data streams, thereby enabling clients to combat marketing fraud and protect against harmful manipulation. By providing accurate insights into social media analytics, Astroscreen helps brands maintain their integrity and defend democracy from deceptive practices online.

Hazy Limited is a London-based company that specializes in data anonymization through artificial intelligence. Founded in 2017, Hazy develops a workflow tool that enables businesses to securely share and utilize data while complying with privacy regulations. The platform automatically anonymizes personal information, allowing organizations to handle evolving datasets without compromising sensitive data. By re-engineering enterprise data, Hazy empowers businesses to enhance decision-making, foster innovation, and create value, all while ensuring that data remains reliable, safe, and trusted. Hazy positions itself as a leader in the synthetic data space, addressing the growing demand for accessible and usable data in an increasingly regulated environment.

Correvate was formed to commercialise a technology that enables the automatic alignment and subsequent analysis of 3D point cloud datasets. The technology was initially created in the Department of Electronic and Electrical Engineering at University College London and then, on 1st January 2018, exclusively licensed to Correvate. It has since been enhanced by both Correvate and UCL into the Vercator® product suite www.vercator.com Vercator software provides fast, robust point cloud processing to enable automated 3D understanding of the environment. The technology can be applied to 3D point cloud datasets created using any scanning technology of any wavelength. Correvate’s first market sector is in construction – where professionals such as surveyors, architects and construction engineers create a ‘digital twin’ of the target project, yielding improvements in productivity well-recognised both by the professionals themselves and by the grant-giving teams in the UK’s Department of Business, Energy and Industrial Strategy.

Intrinsic Semiconductor Technologies specializes in the development of silicon-oxide based resistive random-access memory (RRAM) technologies. The company focuses on creating non-volatile memory solutions that are fully air stable and compatible with complementary metal-oxide-semiconductor (CMOS) processes. Intrinsic's innovative technology can be adapted for various applications, including multilevel memory, hardware acceleration for machine learning, and neuromorphic devices. By utilizing low-power, cost-effective semiconductors and gallium nitride materials, the company enables the integration of its devices into standard CMOS architectures, even at advanced process nodes. This capability allows clients to achieve higher performance under demanding conditions, such as elevated temperatures and frequencies.

Autolus Therapeutics is a biopharmaceutical company based in London, England, focused on developing next-generation programmed T cell therapies for cancer treatment. Founded in 2014 by Tim Funnell and Martin Pule, the company has established a clinical-stage pipeline that includes several innovative therapies, such as Obe-cel (obecabtagene autoleucel) and others designated as AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8. Through its research and development efforts, Autolus aims to advance the field of cancer immunotherapy and improve outcomes for patients battling various types of cancer.

Intract Pharma Limited is a company that specializes in oral drug delivery technologies, particularly aimed at treating gastrointestinal and systemic immune-mediated inflammatory diseases. It focuses on developing proprietary formulation technologies that convert potent injectable biologic medicines into safe, convenient oral pills for patients. By optimizing therapeutic delivery, Intract Pharma addresses the specific needs of individuals suffering from chronic diseases, enhancing the accessibility and usability of effective treatments. The company's innovative approach aims to allow patients to manage their conditions more easily and effectively at home.

Apollo Therapeutics is a biopharmaceutical company that focuses on translating groundbreaking medical research into viable therapeutics. Established as a collaborative venture among three prominent UK universities—Imperial College London, University College London, and the University of Cambridge—and leading pharmaceutical companies including AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation, Apollo Therapeutics aims to accelerate the development of innovative medicines sourced from top British academic research. The company specializes in developing pre-clinical and clinical-stage assets across various therapeutic areas, including oncology, major inflammatory disorders, and rare diseases. Apollo's team of experienced industry scientists works closely with academic institutions and industry partners to create tailored projects that enhance the likelihood of successful therapeutic delivery, ultimately aspiring to improve patient treatment outcomes and have a meaningful impact on healthcare.

Appredict Ltd is a data analysis company that focuses on the app development lifecycle, providing critical insights to app developers. By utilizing advanced machine learning and optimization techniques, the company extracts valuable data that may not be readily apparent, allowing developers to enhance their understanding of application performance and user engagement. This information is designed to help maximize revenue streams from their products, ultimately supporting developers in making informed decisions throughout the app's lifecycle. Appredict's approach is rooted in world-leading research, positioning it as a valuable resource for those in the app development industry.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, specializing in the development of patient-specific immunotherapies designed to combat cancer. Founded in 2016, the company focuses on personalized vaccines and T cell therapies that utilize the body's immune system to target and eliminate cancer cells. Achilles Therapeutics aims to identify and target truncal tumor neoantigens and other markers present on cancer cells, allowing for precise attacks on tumors while sparing healthy tissue. The company is currently conducting clinical trials, including the CHIRON trial for non-small-cell lung cancer and the THETIS trial for recurrent or metastatic melanoma, to evaluate the efficacy and safety of its innovative therapies.

3D Repo Ltd. is a London-based company that develops open source Software as a Service solutions for version control of large-scale 3D architectural models in the cloud. The company specializes in providing cloud-based building information modeling (BIM) version control systems, enabling designers, architects, engineers, and operators to collaborate in real time. Its flagship product, 3D Repo, offers a comprehensive platform that helps the construction industry manage complex projects more effectively, reducing errors and ensuring timely delivery within budget. In addition to its software solutions, 3D Repo also offers on-premise hosting, technical support, and research and development services, including consulting. Established in 2014, the company aims to enhance the efficiency and accuracy of construction projects through innovative digital tools and virtual reality experiences.

Satalia is a developer of advanced algorithm and optimization software that aims to address complex challenges across various industries, including telecommunications, financial services, system design, and drug discovery. The company's flagship product, the SolveEngine, leverages state-of-the-art optimization algorithms to provide solutions for workforce scheduling, vehicle routing logistics, and infrastructure planning. Satalia offers its optimization solutions as a service, available on demand, or as standalone and hybrid cloud options, catering to the unique needs of each client. By simplifying the resolution of optimization problems, Satalia enhances operational efficiencies and facilitates real-time improvements, empowering companies to innovate and maintain competitiveness in a rapidly evolving market.

​Brainminer Ltd has developed an automated system for analysing MR brain scans. Brainminer was founded in 2015 by the Academic inventors and UCLB, the business arm of University College London, with the purpose of commercialising the exciting new machine learning algorithms that have been created for brain analysis at UCL and elsewhere. You can find out more about the company's foundation here. The company has received over £1M of funding from 2 SBRI awards in 2015 and 2016. The company’s first product, DIADEM, is CE marked and medically approved.

HeLP Digital CIC is developing digital interventions in the area of diabetes management in order to provide those whose lives are impacted by diabetes to achieve better self management of their condition. Such as, HeLP Diabetes, a web-based self-management programme and structured education for NHS patients with type 2 diabetes developed by a multidisciplinary group of academics and clinicians headed by Professor Elizabeth Murray, Director of the UCL e-Health Unit.

Bramble Energy Ltd. is a London-based company that designs, develops, and manufactures printed circuit board fuel cells (PCBFC), specifically proton exchange membrane fuel cells (PEMFCs). Founded in 2016, the company utilizes innovative PCB technology to create high-performance and cost-effective fuel cell stacks, including variants of 20 W, 500 W, and 5 kW, along with custom-designed options. By leveraging the capabilities of the global high-volume PCB industry, Bramble Energy stands out as the first fuel cell manufacturer with the capacity to produce gigawatts of fuel cell hardware, a feat that has eluded the battery industry for years. The company's products serve various sectors, including stationary, portable, and automotive applications, offering businesses and energy industry players access to efficient solutions that help reduce energy consumption and lower carbon emissions.

Re:infer is a Conversational Data Intelligence platform designed for enterprises, enabling them to optimize customer experience, enhance scalability, and improve governance. The platform harnesses artificial intelligence and machine learning to provide real-time, structured annotations of the meaning and emotion in conversational data. This allows businesses to achieve end-to-end automation of service requests and streamline their operations. With a zero-code user interface, Re:infer empowers business and domain experts, as well as developers, to rapidly create machine learning or natural language processing models at scale. Originating as a spinout from University College London, Re:infer is backed by prominent investors and has established itself as a leader in transforming service through the democratization of natural language understanding.

SmartTarget is a company that specializes in developing image fusion technology aimed at improving prostate cancer care. Its flagship product, the SmartTarget device, integrates diagnostic information from ultrasound, magnetic resonance imaging (MRI), and previous biopsies to provide clinicians with critical insights into the location, size, and shape of cancer tumors. This CE-marked system is designed to be compatible with various MR and ultrasound equipment, ensuring ease of use and minimal disruption to existing clinical workflows. The intuitive design allows for quick setup, making it suitable for both public and private healthcare sectors. SmartTarget has received support from the UK’s Department of Health and the Wellcome Trust, underscoring its commitment to providing affordable solutions that enhance patient outcomes in prostate cancer diagnosis and treatment.

Yaqrit Limited is a clinical-stage life sciences company focused on developing innovative treatments for advanced liver disease, including cirrhosis, acute-on-chronic liver failure (ACLF), non-alcoholic steatohepatitis (NASH), and non-alcoholic fatty liver disease (NAFLD). With over 650 million individuals affected by chronic liver disease globally, Yaqrit aims to transform the treatment landscape, addressing the limitations of existing options such as antibiotics, laxatives, and liver transplants. By leveraging technical expertise and a global network of collaborators, the company is dedicated to accelerating the development of its therapeutic programs, ultimately striving to improve clinical outcomes and quality of life for severely ill patients suffering from liver-related complications.

Puridify Limited is a bioprocessing company based in Stevenage, United Kingdom, founded in 2013 by Tom Haywood, Oliver Hardick, and Iwan Roberts. The company specializes in developing advanced purification technologies for the manufacturing of industrial biomolecules. Its flagship product, FibroSelect, utilizes a unique nanofiber-based platform that enhances purification efficiency while addressing the limitations found in traditional packed bed chromatography systems. This innovative technology is designed to provide consistent purification performance across various scales, making it suitable for the purification of complex biotherapeutics, including gene therapies, viral vectors, and fusion proteins. By improving the efficiency and cost-effectiveness of biopharmaceutical production, Puridify aims to advance the industry and support the growing demand for high-quality biomolecule products.

AtoCap is a company specializing in microencapsulation technology, initially developed from University College London’s Encapsulation Research Group. The company utilizes advanced electro-hydrodynamic processing methods to create microbubbles and capsules, which are designed to deliver generic antibiotics for urinary tract infections and chemotherapeutics into multi-layered capsules. AtoCap's team combines expertise in academia, clinical research, and commercialization, with a proven track record of translating innovative technologies into commercially viable opportunities that generate significant income and impact for stakeholders and investors.

Autifony Therapeutics Limited is a biotechnology company based in London, United Kingdom, established in 2011. The company specializes in developing innovative medicines aimed at treating hearing disorders, including hearing loss and tinnitus. In addition to its focus on auditory conditions, Autifony is also involved in drug discovery for central nervous system disorders, addressing challenges related to conditions such as schizophrenia, fragile X syndrome, and Alzheimer's disease. By leveraging its platform, the company seeks to alleviate symptoms associated with these disorders and meet the unmet medical needs of patients.

Abcodia is a biotechnology company specializing in the discovery and validation of molecular biomarkers for disease diagnosis and screening, with a particular focus on cancer. Founded in 2010 and headquartered in Cambridge, UK, Abcodia utilizes its unique longitudinal serum biobank and collaborations with academic institutions like UCL, technology platform providers, and leading diagnostic companies to support the entire diagnostic development process. The company offers Roca Test solutions for early ovarian cancer detection, serving customers across multiple states in the US and the United Kingdom.

Nozzle.ai is an eCommerce and advertising optimization platform focused on enhancing sales for online sellers, particularly on Amazon. The company provides a suite of services, including marketplace audits, advertisement optimization, and consulting. Utilizing data science, Nozzle.ai analyzes customer buying patterns to deliver insights on key metrics such as customer repeat order rates, lifetime value, and customer acquisition costs. This data-driven approach enables online sellers and agencies to improve their advertising strategies, ultimately increasing sales and revenue. Founded in 2014 and headquartered in London, Nozzle.ai operates under the umbrella of Beeswax, Inc. after rebranding from MediaGamma Limited in May 2020. The company's offerings also include artificial intelligence consultancy, machine learning operations, and various support services for setting up and managing advertising campaigns.

Trim Tots is a community interest company dedicated to promoting healthy lifestyles among preschool children aged one to five and their caregivers. Developed by child health professionals alongside community artists, Trim Tots offers a 24-week evidence-based program that focuses on obesity prevention through nutrition education, physical activity, and behavior change. The program consists of weekly two-hour sessions that emphasize family involvement and incorporates engaging methods such as art and play to facilitate learning. As the only intervention program with two-year follow-up data, Trim Tots aims to make its healthy lifestyle program accessible to all families, fostering a proactive approach to early childhood growth and development.

ThioLogics is a biotechnology company focused on advancing the field of biologics through its innovative site-specific conjugation platform. This technology enables the selective and stable modification of disulfide bonds or free cysteine in proteins and peptides, resulting in the production of homogeneous products. ThioLogics aims to address the challenges faced in developing antibody-drug conjugates (ADCs) by enhancing their therapeutic indices through greater homogeneity, in comparison to traditional heterogeneous formulations. The company's platform not only improves the efficacy of biologics but also simplifies the associated processes, leading to reduced development costs. Through its advanced techniques, ThioLogics aspires to revolutionize the assembly of next-generation therapeutics.

Gold Standard Phantoms specializes in the development, marketing, and sale of calibration services and devices for quantitative medical imaging, particularly in the realm of MRI technology. The company manufactures cylindrical phantoms that streamline the preparation process by eliminating the need for multiple sample vials, facilitating more efficient calibration. Its offerings include a cloud-based data analysis platform that ensures traceability to standardized values, allowing clinicians, medical physicists, and radiographers to obtain consistent quantitative measurements of diseases across different patients, scanners, and clinical environments. By enhancing the precision of MRI imaging, Gold Standard Phantoms aims to improve diagnostic accuracy and potentially reduce healthcare costs.

Therakind Limited is a pediatric healthcare company based in London, United Kingdom, founded in 2006. The company specializes in creating, developing, and improving pediatric and specialty medicinal products, addressing unmet medical needs in children and other underrepresented patient groups. Notable products include Buccolam, which treats prolonged acute convulsive seizures in children, and Ayendi, an intranasal pain control solution for pediatric patients. Therakind focuses on developing niche medicines in challenging therapeutic areas, including cytotoxic, diabetic, sedation, antibiotic, and endocrinology treatments. By offering more patient-friendly dosing options, Therakind aims to enhance medicine adherence and expand access to safe and effective treatments for vulnerable populations.

CGT Catapult is a UK-based centre of excellence dedicated to advancing the cell and gene therapy sector globally. Supported by Innovate UK, it aims to facilitate the translation of early-stage research into commercially viable therapies. Based in central London with over 120 experts and state-of-the-art laboratories, CGT Catapult offers a comprehensive platform for product development, clinical trials, manufacturing, regulatory support, health economics, and market access expertise. Additionally, they are constructing a £55 million large-scale GMP manufacturing centre to accelerate the delivery of cell and gene therapies to patients worldwide.

Endomag is a medical technology company focused on enhancing cancer care standards globally. Founded in 2007 as a spin-out from the University of Houston and University College London, the company is headquartered in Cambridge, United Kingdom. Endomag develops innovative magnetic sensing technology that provides minimally invasive surgical guidance, which helps physicians accurately target and remove tumors. Its key products, including the Sentimag probe, Magseed marker, and Magtrac node marker, are utilized by leading physicians and cancer centers worldwide. The company's mission is to enable women with breast cancer to avoid unnecessary surgeries and achieve better outcomes when surgery is required. To date, Endomag has assisted over 70,000 women globally in accessing more precise and less invasive breast cancer care through its network of distributors across Europe, the Middle East, Africa, and Australasia.

CBK Sci Con are a consultancy devoted to the provision of high end scientific, technical and management advice to your business in e-science domains. CBK Sci Con was formed by one of UCL’s leading computational scientists, Professor Peter Coveney, Paul Best – an industrialist with a career in complex engineered systems and Dr Riam Kanso, a cognitive neuroscientist working in computational life and medical sciences. They have brought their combined experience of over 60 years across industry and academe, to form CBK to develop and apply e-science expertise to complex business problems.

SoftV is a new generation of gamification company, based in London focussing on Neuroscience and related medical applications. Our aim is to develop and deliver apps, games and online services to the benefit of the wider public and patient community on Mobile, Tablet, Console and PC for use at home and in a clinical context. The two company founders have over 30 years of collective experience within interactive systems and games development.

Newtec Vascular Products Ltd is a medical device company based in Liverpool, United Kingdom, that specializes in developing innovative solutions for cardiovascular surgery. Founded in 2013, the company focuses on addressing Neo Intimal Hyperplasia, a condition characterized by the blockage of blood vessels caused by scar tissue following vascular graft surgery. Their flagship product, FloGuardian™, has demonstrated promising efficacy in pre-clinical studies and is currently preparing for first-in-man trials. With the potential to be utilized in over 2 million procedures annually, Newtec Vascular Products aims to tap into a significant market opportunity exceeding £800 million, ultimately enhancing the safety and effectiveness of vascular surgeries for medical practitioners and cardiologists.

Amalyst Limited is a company focused on developing advanced catalysts for fuel cell and electrolyser applications. Founded in 2012 and based in London, United Kingdom, the company specializes in creating electrode catalysts that serve as essential components in proton exchange membrane fuel cells and water electrolysers. Amalyst's technology aims to replace traditional platinum-based catalysts with more efficient alternatives, offering solutions that can be integrated seamlessly into existing systems. Their innovative approach includes the development of catalysts that can be supported on various materials, including surface area carbons and graphites, thereby enhancing the performance and sustainability of energy conversion technologies.

Canbex Therapeutics, Ltd. is a London-based company focused on developing peripherally-acting cannabinoid agonists aimed at treating spasticity associated with multiple sclerosis and other neurodegenerative diseases. Founded in 2005, the company addresses the debilitating symptoms of spasticity, which include involuntary muscle spasms and stiffness. Canbex Therapeutics strives to enhance the quality of life for individuals suffering from this serious and often incurable condition, with the objective of establishing a new standard in the treatment of spasticity.

Domainex Ltd. is a biotechnology company based in Saffron Walden, United Kingdom, that specializes in contract research and manufacturing services focused on drug discovery. Established in 2001, the company provides a comprehensive range of services, including medicinal and computational chemistry, protein expression and purification, biochemical assay development, and DMPK analysis. Domainex is known for its expertise in developing advanced medicines through innovative technologies, including biochemical binding techniques, particularly for oncology drugs and treatments for inflammatory diseases. The company has a significant emphasis on hit identification and candidate drug synthesis, utilizing both virtual and fragment-based approaches to address complex drug discovery challenges. In 2007, Domainex merged with NCE Discovery, enhancing its capabilities in both biological and chemical research.

Helicon Health is a medical technology development company focused on enhancing patient outcomes for individuals with chronic diseases. The company offers a range of digital healthcare services designed to improve the management of multiple long-term conditions. Its suite of solutions includes an electronic health record system, an anticoagulant advisory system, tools for patient self-monitoring, and telemedicine services. By utilizing these technologies, Helicon Health aims to facilitate early detection, diagnosis, and treatment of chronic diseases, ultimately reducing healthcare costs and improving the quality of care for patients.

Imanova Limited is a translational imaging center based in London, United Kingdom, specializing in research and drug development services. Founded in 2011, Imanova leverages its world-leading expertise in imaging sciences to enhance the understanding of diseases and facilitate the drug development process. The company operates as a joint venture with shareholders that include the UK's Medical Research Council and three prestigious London universities: Imperial College London, King’s College London, and University College London. Imanova excels in developing applications for positron emission tomography and magnetic resonance imaging, particularly for pre-clinical studies. Its strong academic foundation and extensive connections with clinicians and scientists enable Imanova to provide unparalleled support in the drug development pipeline.

Nanogenics Ltd is a research-focused biotechnology company dedicated to advancing gene therapy through the development of artificial viruses. Central to its innovation is LipTide, a synthetic peptide nanoparticle that serves as a customizable delivery system. This product mimics natural viruses while circumventing the challenges associated with traditional viral delivery methods. By enabling targeted delivery of various therapeutic payloads to specific cell types, LipTide enhances delivery rates and specificity compared to conventional liposomal vectors. Nanogenics aims to collaborate with innovative partners to bring groundbreaking treatments to market, positioning its technology as a transformative solution in the field of gene therapy.

Chirp is a technology company focused on simplifying connectivity through sound-based solutions. Its innovative machine-to-machine communications software allows devices equipped with loudspeakers or microphones to share data using inaudible sound waves. This technology facilitates seamless and scalable interconnection among millions of devices, enhancing user experiences and adding value to existing hardware. Chirp's commitment to research and development, supported by a world-class engineering team, positions it as a leader in the field of sound-based data exchange.

Canbex Therapeutics, Ltd. is a London-based company focused on developing peripherally-acting cannabinoid agonists aimed at treating spasticity associated with multiple sclerosis and other neurodegenerative diseases. Founded in 2005, the company addresses the debilitating symptoms of spasticity, which include involuntary muscle spasms and stiffness. Canbex Therapeutics strives to enhance the quality of life for individuals suffering from this serious and often incurable condition, with the objective of establishing a new standard in the treatment of spasticity.